Phase II Optimization, Open-Label Clinical Trial of Zalypsis® (PM00104) in Relapsed/Refractory Multiple Myeloma Patients

被引：0

作者：

Ocio, Enrique M. ^{[1
]}

De La Rubia, Javier ^{[2
]}

Oriol-Rocafiguera, Albert ^{[3
]}

Blade, Joan ^{[4
]}

Rodriguez, Jose ^{[5
]}

Coronado, Cinthya ^{[5
]}

Martin Sanchez, Jesus ^{[6
]}

Isabel Teruel, Ana ^{[7
]}

Hernandez-Maraver, Dolores ^{[8
]}

Prosper, Felipe ^{[9
]}

San-Miguel, Jesus. F.

机构：

[1] Hosp Univ Salamanca, Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain

[2] Hosp Univ La Fe, Valencia, Spain

[3] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

[4] Hosp Clin Barcelona, Barcelona, Spain

[5] PharmaMar, Madrid, Spain

[6] Hosp Univ Virgen del Rocio, Seville, Spain

[7] Hosp Clin Univ Valencia, Valencia, Spain

[8] Hosp La Paz, Madrid, Spain

[9] Univ Navarra Clin, Pamplona, Spain

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.4041.4041

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4041

引用

页数：2

共 50 条

[31] RMPT in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase II Clinical Trial
Palumbo, A.
Larocca, A.
Sanpaolo, G.
Falcone, A. P.
Federico, V.
Canepa, L.
Crugnola, M.
Baldini, L.
Magarotto, V.
Falco, P.
Petrucci, M. T.
Boccadoro, M.
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S14 - S15
[32] An Open-label Dose-escalation Study of BIBF 1120 in Patients with Relapsed or Refractory Multiple Myeloma
Kropff, Martin
Kienast, Joachim
Bisping, Guido
Berdel, Wolfgang E.
Gaschler-Markefski, Birgit
Stopfer, Peter
Stefanic, Martin
Munzert, Gerd
ANTICANCER RESEARCH, 2009, 29 (10) : 4233 - 4238
[33] A phase 1, open-label, dose-escalation study of pralatrexate incombination with bortezomib in patients with relapsed/refractory multiple myeloma
Dunn, Tamara J.
Dinner, Shira
Price, Elizabeth
Coutre, Steven E.
Gotlib, Jason
Hao, Ying
Berube, Caroline
Medeiros, Bruno C.
Liedtke, Michaela
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) : 253 - 259
[34] Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Dimopoulos, Meletios A.
Goldschmidt, Hartmut
Niesvizky, Ruben
Joshua, Douglas
Chng, Wee-Joo
Oriol, Albert
Orlowski, Robert Z.
Ludwig, Heinz
Facon, Thierry
Hajek, Roman
Weisel, Katja
Hungria, Vania
Minuk, Leonard
Feng, Shibao
Zahlten-Kumeli, Anita
Kimball, Amy S.
Moreau, Philippe
LANCET ONCOLOGY, 2017, 18 (10): : 1327 - 1337
[35] An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors
Oechsle, Karin
Honecker, Friedemann
Kollmannsberger, Christian
Rick, Oliver
Gruenwald, Victor
Mayer, Frank
Hartmann, Joerg T.
Bokemeyer, Carsten
ANTI-CANCER DRUGS, 2007, 18 (03) : 273 - 276
[36] Trial in progress: an open-label, multicenter, phase 1 study for IGM-2644 in participants with relapsed and/or refractory multiple myeloma (RRMM)
Funke, Roel
Schade, Henning
Berdeja, Jesus
Li, Keyu
Kotturi, Maya
Hernandez, Genevive
Guan, Yinghui
Deodhar, Malavika
Durant, Dominique
Takimoto, Chris
Manley, Thomas
Hart, Kevin
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S60 - S61
[37] SAFETY AND EFFICACY UPDATE OF PX-171-004, AN OPEN-LABEL PHASE II TRIAL OF CARFILZOMIB IN RELAPSED MULTIPLE MYELOMA
Siegel, D.
Wang, M.
Stewart, K.
Jakubowiak, A.
Jagannath, S.
McDonagh, K.
Kukreti, V.
Lonial, S.
Cruickshank, S.
Vij, R.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 191 - 191
[38] First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours
T A Yap
H Cortes-Funes
H Shaw
R Rodriguez
D Olmos
R Lal
P C Fong
D S Tan
D Harris
J Capdevila
C Coronado
V Alfaro
A Soto-Matos
C Fernández-Teruel
M Siguero
J M Tabernero
L Paz-Ares
J S de Bono
J A López-Martin
British Journal of Cancer, 2012, 106 : 1379 - 1385
[39] Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study
Larocca, Alessandra
Montefusco, Vittorio
Bringhen, Sara
Rossi, Davide
Crippa, Claudia
Mina, Roberto
Galli, Monica
Marcatti, Magda
La Verde, Giacinto
Giuliani, Nicola
Magarotto, Valeria
Guglielmelli, Tommasina
Rota-Scalabrini, Delia
Omede, Paola
Santagostino, Alberto
Baldi, Ileana
Carella, Angelo Michele
Boccadoro, Mario
Corradini, Paolo
Palumbo, Antonio
BLOOD, 2013, 122 (16) : 2799 - 2806
[40] A phase II trial of Gleevec™ in patients with refractory/relapsed myeloma
Dispenzieri, A
Witzig, TE
Lacy, MQ
Geyer, SM
Kimlinger, T
Rajkumar, SV
Greipp, PR
Fonseca, R
Lust, JA
Zeldenrust, SR
Hayman, SR
Gertz, MA
BLOOD, 2004, 104 (11) : 665A - 665A

← 1 2 3 4 5 →